Ropinirole therapy for Parkinson’s disease

References

• Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl. J. Med. 342(20), 1484–1491 (2000).
   Google Scholar
• ••The first long-term study examining the onset of dyskinesia in patients randomly assigned to either levodopa or ropinirole.
   Google Scholar
• Pramipexole versus levodopa as initial treatment for Parkinson's disease: a randomized controlled trial. Parkinson Study Group. JAMA 284(15), 1931–1938 (2000).
   PubMedGoogle Scholar
• Pahwa R, Wilkinson SB, Overman J, Lyons KE. Bilateral subthalamic stimulation in patients with Parkinson's disease: long-term follow-up.j Neurosurg. 99(1), 71–77 (2003).
   Google Scholar
• Coldwell MC, Boyfield I, Brown T, Hagan JJ, Middlemiss DN. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol 127(7), 1696–1702 (1999).
   Google Scholar
• Eden RJ, Costal]. B, Domeney AM et al. Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol Biochem. &hay 38(1), 147–154 (1991).
   Google Scholar
• Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 45(3 Suppl. 3), S6—S12 (1995).
   Google Scholar
• Brooks DJ, Torjanski N, Bum DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. J. Neural. Transm. 45, 231–238 (1995).
   Google Scholar
• Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Pharmacokinet. 39(4), 243–254 (2000).
   Google Scholar
• Ramji JV, Keogh JP, Blake TJ etal. Disposition of ropinirole in animals and man. Xenobiotica 29 (3), 311–325 (1999).
   PubMed Web of Science ®Google Scholar
• Kuzel MD. Ropinirole: a dopamine agonist for the treatment of Parkinson's disease. Am.Health Syst. Pharm. 56(3), 217-224(1999).
   Google Scholar
• Swagzdis JE, Wittendorf RVV, DeMarinis RM, Mico BA. Pharmacokinetics of dopamine-2 agonists in rats and dogs. J. Pharm. Sci. 75(10), 925–928 (1986).
   Google Scholar
• Bloomer JC, Clarke SE, Chenery RJ. hi Vitrn identification of the P450 enzymes responsible for the metabolism of ropinirole. Drug Metab. Divas. 25 (7), 840–844 (1997).
   Google Scholar
• Brefel C, Thalamas C, Rayet S etal. Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients. Br. J. Clin. Pharmacol. 45(4), 412–415 (1998).
   Google Scholar
• Beerahee A, Nichols AT, Aluri J et al. Population pharmacokinetics of ropinirole in patients with Parkinson's disease. Br. j Clin. Pharmacol. 43, 556–557 (1997).
   Google Scholar
• Wynalda MA, Wienkers LC. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug-Metab. Dispos. 25(10), 1211–1214 (1997).
   Google Scholar
• Fukuzaki K, Kamenosono T, Kitazumi K, Nagata R. Effects of ropinirole on motor behavior in MPTP-treated common marmosets. Pharmacol Biochem. &hay. 67(1), 121–129 (2000).
   Google Scholar
• Pearce RK, Baneiji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. May Disorcl. 13(2), 234–241 (1998).
   Google Scholar
• Adler CH, Sethi KD, Hauser RA etal. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 49(2), 393–399 (1997).
   Google Scholar
• Brooks DJ, Abbott RJ, Lees AJ et al A Placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin. Neuropharmacol 21 (2), 101–107 (1998).
   Google Scholar
• Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology53(2), 364–370 (1999).
   Google Scholar
• •One of the few randomized studies comparing the safety and efficacy of two dopamine agonists.
   Google Scholar
• Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin. Neuropharmacol 19(3), 234–245 (1996).
   PubMed Web of Science ®Google Scholar
• Lieberman A, Olanow CW, Sethi K et al A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neumlogy51(4), 1057–1062 (1998).
   PubMed Web of Science ®Google Scholar
• Whone AL, Watts RL, Stoessl AJ et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neural 54(1), 93–101 (2003).
   PubMed Web of Science ®Google Scholar
• ••Examines the progression of disease inpatients randomly assigned to ropinirole or levodopa using positron emission tomography imaging as a marker.
   Google Scholar
• Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 838(1–2), 51–59 (1999).
   Google Scholar
• Rakshi JS, Pavese N, Uema T et al A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study. Neural. Trans. 109(12), 1433–1443 (2002).
   Google Scholar
• Physicians' Desk Reference (2004).
   Google Scholar
• Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52(9), 1908–1910 (1999).
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks and Parkinson's disease treatment. Lancet 355(9212), 1333–1334 (2000).
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Thalamas C, Montastruc JL, Castro-Caldas A, Rascol O. Levodopa monotherapy can induce 'sleep attacks' in Parkinson's disease patients. j Neural 248(5), 426–427 (2001).
   PubMed Web of Science ®Google Scholar
• Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson's disease: a survey by the Canadian Movement Disorders Group. JAIVIA 287(4), 455–463 (2002).
   PubMed Web of Science ®Google Scholar
• Todman DH, Oliver WA, Edwards RL. Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease. Clin. Exp. Neural 27,79–82 (1990).
   Google Scholar
• Lanier WL. Additional insights into pergolide-associated valvular heart disease. Mayo Clin. Proc. 78(6), 684–686 (2003).
   Google Scholar
• Lund BC, Neiman RF, Perry PJ. Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis. Pharmacotherapy19(12), 1437–1438 (1999).
   PubMed Web of Science ®Google Scholar
• Lang AE, Lees A. Management of Parkinson's Disease: an evidence-based review. Mov. Disord. 17(S4), S1—S166 (2002).
   Google Scholar
• ••Provides a detailed overview of the varioustreatments for Parldnson's disease using an evidence-based approach.
   Google Scholar
• Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 58(1), 11–17 (2002).
   PubMed Web of Science ®Google Scholar
• ••Represents the official practice parametersof the American Academy of Neurology for the initiation of treatment for Parkinson's disease using an evidence-based approach.
   Google Scholar
• Ondo W Ropinirole for restless legs syndrome. Mov. Disord 14 (1), 138–140 (1999).
   PubMedGoogle Scholar
• Saletu M, Anderer P, Saletu B et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology 41(4), 190–199 (2000).
   Google Scholar
• Saletu B, Gruber G, Saletu M et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology 41(4), 181–189 (2000).
   Google Scholar
• Trenkwalder C, Garcia-Borreguero D, Montagna P et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo-controlled study in 10 European countries. J. Neural. Neurosurg. Psychiatry75(1), 92–97 (2004).
   Google Scholar
• ••A large multicenter, randomized trial examining the use of ropinirole for restless legs syndrome.
   Google Scholar
• Adler CH, Hauser RA, Sethi K et al. Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology62, 1405–1407 (2004).
   PubMed Web of Science ®Google Scholar
• Shulman LM, Minagar A, Rabinstein A, Weiner WJ. The use of dopamine agonists in very elderly patients with Parkinson's disease. May Disonl. 15,664–668 (2000).
   PubMed Web of Science ®Google Scholar